Cargando…

Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010

OBJECTIVES: To determine the rates of fluoroquinolone resistant (FQR) in gram-negative bacilli urinary tract infections (UTIs) in a global population. METHODS: The Study for Monitoring Antimicrobial Resistance Trends (SMART) collected 1,116 FQR gram-negative urinary pathogens from hospitalized patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouchillon, Sam, Hoban, Daryl J, Badal, Robert, Hawser, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447161/ https://www.ncbi.nlm.nih.gov/pubmed/23002406 http://dx.doi.org/10.2174/1874285801206010074

Ejemplares similares

421 Activity of Tigecycline and Comparators Against Lower Respiratory Tract (LRT) Isolates of Enterobacteriaceae from North America and Europe: 2009-2013
por: Hoban, Daryl, et al.
Publicado: (2014)

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011
por: Morrissey, Ian, et al.
Publicado: (2013)

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015
por: Karlowsky, James A., et al.
Publicado: (2017)

1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017
por: Lob, Sibylle, et al.
Publicado: (2018)

Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and urinary tract infections: updated report of SMART 2015 in China
por: Zhang, Hui, et al.
Publicado: (2018)

412 In vitro Activity of Key Antimicrobial Agents Against Bacterial Isolates From Intra-abdominal (IAI) and Skin and Wound (SW) Infections: Europe 2004-2013
por: Hoban, Daryl, et al.
Publicado: (2014)

Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens
por: Schwaber, Mitchell J., et al.
Publicado: (2004)

709. Activity of Key β-Lactam Agents Against Gram-Negative Bacilli From ICU Patients with Lower Respiratory Tract Infections, SMART United States 2015–2017
por: Lob, Sibylle, et al.
Publicado: (2018)

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014
por: Yang, Qiwen, et al.
Publicado: (2017)

413 In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in the United States – TEST 2011-2013
por: Hackel, Meredith, et al.
Publicado: (2014)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

Novel Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery
por: Coba-Males, Manuel Alejandro, et al.
Publicado: (2023)

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
por: Hoban, Daryl J, et al.
Publicado: (2015)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)
por: Ponce-de-Leon, Alfredo, et al.
Publicado: (2018)

1787. County Level Association Between the Rate of Fluoroquinolone-Resistance Gram Negative Bacteria and Fluoroquinolone Utilization in Kansas
por: Fulmer, Robert D, et al.
Publicado: (2022)

490 High Dose Tigecycline for the Treatment of Multi-Drug Resistant Gram Negative Urinary Tract Infections
por: Sam, Sharon, et al.
Publicado: (2014)

1587. Activity of Ceftolozane/Tazobactam against Gram-Negative Isolates from Lower Respiratory Tract Infections – SMART United States 2018
por: Lob, Sibylle, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

715 Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
por: Brigmon, Matthew, et al.
Publicado: (2014)

150. Urinary Tract-Associated Gram-Negative Bacteremia: Impact of Treatment Duration
por: Badwal, Jasmin K, et al.
Publicado: (2019)

1433. Predictive Models for Antibiotic Coverage of Gram-Negative Urinary Tract Infections
por: Hebert, Courtney, et al.
Publicado: (2019)

Increased resistance of gram-negative urinary pathogens after kidney transplantation
por: Korth, Johannes, et al.
Publicado: (2017)

Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017)
por: Cantón, Rafael, et al.
Publicado: (2019)

N1-Benzofused Modification of Fluoroquinolones Reduces Activity Against Gram-Negative Bacteria
por: Laws, Mark, et al.
Publicado: (2020)

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories
por: Sfeir, Maroun M
Publicado: (2020)

Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases
por: Richter, Sara N., et al.
Publicado: (2007)

Gram-negative resistance and need for ICU among urinary tract infections in the United States
por: Zilberberg, M, et al.
Publicado: (2013)

Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
por: Lee, Rachael A, et al.
Publicado: (2017)

1041 Economic Burden Associated with Key Gram-negative Pathogens among Patients with Complicated Urinary Tract Infections across US Hospitals
por: Mocarski, Michelle, et al.
Publicado: (2014)

Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study
por: Zhang, Hui, et al.
Publicado: (2019)

1609. Epidemiology and Susceptibility to Imipenem/Relebactam of Gram-Negative Pathogens from Patients with Lower Respiratory Tract Infections – SMART United States 2017-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections
por: Bidell, Monique R., et al.
Publicado: (2017)

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
por: Shealy, Stephanie C., et al.
Publicado: (2020)

A Dietary Source of High Level of Fluoroquinolone Tolerance in mcr-Carrying Gram-Negative Bacteria
por: Xu, Tianqi, et al.
Publicado: (2023)

A Pattern of Antibiotic Resistance in Gram-Negative Rods Causing Urinary Tract Infection in Adults
por: Ali, Syed Asad, et al.
Publicado: (2021)

Use of urinary gram stain for detection of urinary tract infection in childhood.
por: Arslan, Sükrü, et al.
Publicado: (2002)

Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance
por: Bedenić, Branka, et al.
Publicado: (2021)

Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010
por: Fernández-Canigia, Liliana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i8jd9bvedbqlr0dkeakh03mlr1